Drugs Made In America Acquisition II Corp. $DMII Shares Sold by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its holdings in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) by 12.5% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 350,000 shares of the company’s stock after selling 50,000 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Drugs Made In America Acquisition II were worth $3,490,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Magnetar Financial LLC purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $26,730,000. Glazer Capital LLC purchased a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at $23,264,000. First Trust Capital Management L.P. acquired a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at $20,474,000. Hudson Bay Capital Management LP acquired a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at $19,493,000. Finally, Millennium Management LLC acquired a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at $14,850,000.

Analysts Set New Price Targets

Several analysts recently issued reports on DMII shares. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

Shares of NASDAQ DMII opened at $10.08 on Thursday. Drugs Made In America Acquisition II Corp. has a 1 year low of $9.86 and a 1 year high of $10.11. The stock’s 50-day simple moving average is $10.07.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.